News

Orasis Pharmaceuticals announces approval of Qlosi, a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials.

Orasis Pharmaceuticals CEO Elad Kedar and COO Paul Smith sat down with David Hutton to discuss the FDA approval of Qlosi, a preservative-free low-dose eyedrops for presbyopia.

Ocular graft-vs-host disease is not the garden variety dry eye.

Eclipsing 100,000 doses sold to retinal specialists within the first full year after commercial launch is an important milestone for the company.

Phase 2/3 SIGLEC trial are underway. Data shared at EURETINA 2023 shows continued safety with no drug-related adverse events thus far in cohorts 1, 2, 3, and 4.

EVO ICLs, which evolved from early generation ICLs, offer a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for vision correction.

Mutations in the EMC1 gene appear to be associated with FEVR, a severe ocular condition.

According to a human study of older adults, grape intake improved macular pigment accumulation and downregulated harmful biomarkers.

Academy’s program will take place in San Francisco, California, 3-6 November 2023, before returning to Chicago, Illinois in 2024

Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.

At the 56th annual Retina Society congress in New York, David Boyer, MD, gave a presentation titled, "Subgroup analyses of phase 1 DAVIO Trial of EYP-1901 demonstrating reduced treatment burden in wet age-related macular degeneration."

In the wake of the October 7 surprise attack by Hamas, Israel finds itself thrust into war, and ophthalmologists are working to provide the best care they can under the conditions they find themselves in.

Sophie Bakri, MD, MBA, shared insights from her presentation, "Comparison of the Antiangiogenic Profile of Tyrosine Kinase Inhibitors Vorolanib, Axitinib, and Sunitinib."

Researchers note their work reports a novel candidate gene for FEVR, which expands the spectrum of EMC1 variants and EMC1-related phenotypes, providing evidence for the prenatal diagnosis of candidate disease-causing EMC1 variants in FEVR.

The patent covers the company’s development of this cell transplant therapy as a treatment for geographic atrophy.

According to the United States Attorney’s Office Southern District of Texas, Michael Hochman, MD, is set to be arraigned Oct. 12 before U.S. Magistrate Judge Christopher dos Santos.

With investigations into CVI in the early phases, collaboration across the Atlantic is crucial

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI.

The use of silicone-free syringes advised with these drops.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.

The investigators performed clinical examinations and obtained fundus photographs and inferior optical coherence tomography (OCT) images for both treatments at baseline and on days 1, 3, 8, 15, and 56 after the injections.

A modified endolaser setup was found to be safe and efficient for use during chandelier scleral buckling.

The ANTERION from Heidelberg Engineering offers a range of advanced diagnostic tools, including IOL power calculation, corneal topography, and tomography.

Michael Engelbert, MD, PhD, discusses how personalized faricimab dosing shows promise in extending dosing intervals for patients with wet age-related macular degeneration, which can enhance long-term treatment outcomes and patient adherence.

Prevent Blindness emphasizes the importance of proper eye protection, as exposure to the sun during an eclipse can cause "eclipse blindness" or retinal burns, which can be temporary or permanent.

Researchers at the Warsaw, Poland-based International Center for Translational Eye Research decided to change that by introducing a new imaging method derived from optical coherence tomography. This led to the creation of even more advanced spatio-temporal optical coherence tomography.

According to Sun Pharmaceutical Industries, the study design mirrors real-world experience with dry eye disease, including allowing use of artificial tears and measurement of CFS in all 5 corneal zones.